Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Effects of morning vs. evening teriparatide injection on bone mineral density and bone turnover markers in postmenopausal osteoporosis

D. Michalska, M. Luchavova, V. Zikan, I. Raska, AA. Kubena, JJ. Stepan,

. 2012 ; 23 (12) : 2885-91.

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc13024459

Grantová podpora
NS10564 MZ0 CEP - Centrální evidence projektů

Digitální knihovna NLK
Plný text - Článek
Zdroj

E-zdroje Online Plný text

NLK ProQuest Central od 1997-01-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2000-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest) od 1997-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1997-01-01 do Před 1 rokem
Public Health Database (ProQuest) od 1997-01-01 do Před 1 rokem

UNLABELLED: A 12-month morning teriparatide (TPTD) administration resulted in a larger increase in the lumbar spine bone mineral density (BMD) than the evening application. The results indicate that the response of bone cells to teriparatide treatment depends on dosing time. INTRODUCTION: The aim of this study was to assess the long-term effects of the morning vs. the evening teriparatide administration on BMD and bone turnover markers (BTMs) in postmenopausal osteoporosis. METHODS: Fifty women with established postmenopausal osteoporosis were randomized to 12-month treatment with 20 μg of TPTD, administered daily in the morning or in the evening. The BMD and serum concentrations of C-terminal telopeptide of type I collagen, N-terminal propeptide of type I procollagen (PINP), and tartrate-resistant acid phosphatase isoform 5b (TRAP 5b) were measured at baseline, after 6 and 12 months. General linear model-repeated measurements were used to analyze the data. RESULTS: After 12 months, the lumbar spine BMD grew markedly (p < 0.001) with a significantly greater increase in the morning arm compared to the evening arm (9.1% vs. 4.8%, respectively, p < 0.05). The BMD at the distal radius significantly decreased (p < 0.001), with no differences between the arms. The BMD at proximal femur did not change significantly. After 6 months, the BTMs were significantly increased compared with baseline (p < 0.001). The increases in the evening arm vs. the morning arm, however, were more pronounced in PINP (+358% vs. +215%, respectively) and in TRAP 5b (+70% vs. +37%, respectively) (both p < 0.05). CONCLUSION: 12-month morning administration of TPTD resulted in a larger increase in the lumbar spine BMD than the evening application. The timing of TPTD administration may be important for its efficacy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc13024459
003      
CZ-PrNML
005      
20141023103750.0
007      
ta
008      
130703s2012 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00198-012-1955-4 $2 doi
035    __
$a (PubMed)22426952
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Michalska, D $u Department of Internal Medicine III-Department of Endocrinology and Metabolism, General University Hospital and First Faculty of Medicine, Charles University, Prague, U Nemocnice 1, 128 08, Prague 2, Czech Republic.
245    10
$a Effects of morning vs. evening teriparatide injection on bone mineral density and bone turnover markers in postmenopausal osteoporosis / $c D. Michalska, M. Luchavova, V. Zikan, I. Raska, AA. Kubena, JJ. Stepan,
520    9_
$a UNLABELLED: A 12-month morning teriparatide (TPTD) administration resulted in a larger increase in the lumbar spine bone mineral density (BMD) than the evening application. The results indicate that the response of bone cells to teriparatide treatment depends on dosing time. INTRODUCTION: The aim of this study was to assess the long-term effects of the morning vs. the evening teriparatide administration on BMD and bone turnover markers (BTMs) in postmenopausal osteoporosis. METHODS: Fifty women with established postmenopausal osteoporosis were randomized to 12-month treatment with 20 μg of TPTD, administered daily in the morning or in the evening. The BMD and serum concentrations of C-terminal telopeptide of type I collagen, N-terminal propeptide of type I procollagen (PINP), and tartrate-resistant acid phosphatase isoform 5b (TRAP 5b) were measured at baseline, after 6 and 12 months. General linear model-repeated measurements were used to analyze the data. RESULTS: After 12 months, the lumbar spine BMD grew markedly (p < 0.001) with a significantly greater increase in the morning arm compared to the evening arm (9.1% vs. 4.8%, respectively, p < 0.05). The BMD at the distal radius significantly decreased (p < 0.001), with no differences between the arms. The BMD at proximal femur did not change significantly. After 6 months, the BTMs were significantly increased compared with baseline (p < 0.001). The increases in the evening arm vs. the morning arm, however, were more pronounced in PINP (+358% vs. +215%, respectively) and in TRAP 5b (+70% vs. +37%, respectively) (both p < 0.05). CONCLUSION: 12-month morning administration of TPTD resulted in a larger increase in the lumbar spine BMD than the evening application. The timing of TPTD administration may be important for its efficacy.
650    _2
$a kyselá fosfatasa $x krev $7 D000135
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a kostní denzita $x účinky léků $7 D015519
650    _2
$a inhibitory kostní resorpce $x aplikace a dávkování $x terapeutické užití $7 D050071
650    _2
$a vápník $x krev $7 D002118
650    _2
$a kolagen typu I $x krev $7 D024042
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a injekce subkutánní $7 D007279
650    _2
$a izoenzymy $x krev $7 D007527
650    _2
$a bederní obratle $x patofyziologie $7 D008159
650    _2
$a lidé středního věku $7 D008875
650    _2
$a postmenopauzální osteoporóza $x krev $x farmakoterapie $x patofyziologie $7 D015663
650    _2
$a peptidové fragmenty $x krev $7 D010446
650    _2
$a peptidy $x krev $7 D010455
650    _2
$a fosfáty $x krev $7 D010710
650    _2
$a prokolagen $x krev $7 D011347
650    _2
$a teriparatid $x aplikace a dávkování $x terapeutické užití $7 D019379
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Luchavova, M $u -
700    1_
$a Zikan, V $u -
700    1_
$a Raska, I $u -
700    1_
$a Kubena, A A $u -
700    1_
$a Stepan, J J $u -
773    0_
$w MED00003659 $t Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA $x 1433-2965 $g Roč. 23, č. 12 (2012), s. 2885-91
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22426952 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20130703 $b ABA008
991    __
$a 20141023103748 $b ABA008
999    __
$a ok $b bmc $g 988139 $s 822839
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2012 $b 23 $c 12 $d 2885-91 $i 1433-2965 $m Osteoporosis international $n Osteoporos Int $x MED00003659
GRA    __
$a NS10564 $p MZ0
LZP    __
$a Pubmed-20130703

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...